SBPH SPRING BANK PHARMACEUTICALS

Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference

Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference

HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020.

Martin Driscoll, Spring Bank’s President and CEO, will be providing a corporate presentation on June 2, 2020 from 4:00pm to 4:25pm EDT.

The corporate presentation will be accessible in the Investors & Media section of the company's website at . There are no planned webcasts for this event.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, please visit .

Investors:

LifeSci Advisors, LLC

Ashley R. Robinson

(617) 535-7742

Media:

McNeil, Gray & Rice

Kristin Nugent

Senior Account Supervisor

(617) 367-0100

Source: Spring Bank Pharmaceuticals, Inc.

EN
26/05/2020

Underlying

SBPHSPRING BANK PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SPRING BANK PHARMACEUTICALS

 PRESS RELEASE
Free
SBPH SPRING BANK PHA...

Spring Bank Pharmaceuticals Stockholders Approve Combination with F-st...

Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 20, 2020 HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Li...

November 19, 2020 1 EN
 PRESS RELEASE
Free
SBPH SPRING BANK PHA...

Spring Bank Pharmaceuticals Announces Special Dividend of Contingent V...

Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable on a post-reve...

November 6, 2020 1 EN
 PRESS RELEASE
Free
SBPH SPRING BANK PHA...

Spring Bank Announces Poster Presentation at the 2020 Society for Immu...

Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. SB 11285 is Spring Bank’s intravenously (IV)-administered S...

November 2, 2020 1 EN
 PRESS RELEASE
Free
SBPH SPRING BANK PHA...

Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and ...

Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to additional monotherapy and combination dosing cohorts Abstracts for IV SB 11285 accepted by major oncology scientific conferences for presentation in Q3 and Q4 2020 HOPKINTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical comp...

August 10, 2020 1 EN
 PRESS RELEASE
Free
SBPH SPRING BANK PHA...

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine t...

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programsCombined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate contingent value rights related to Spring Bank’s STING agonist and STING antagonist programsCompanies to host joint conference call on July 30, 2020 at 7:30 a.m. Eastern Time HOPKINTON, Mass. and CAMBRIDGE, Uni...

July 29, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch